167 related articles for article (PubMed ID: 20849438)
21. Application of the HALF index obviates the need for liver biopsy in half of all patients with chronic hepatitis B.
Lee HJ; Seo YS; Kim DJ; Kang HS; An H; Kim JH; Cheong JY; Yim HJ; Yeon JE; Lee HS; Byun KS; Cho SW; Kim DJ; Um SH; Kim CD; Ryu HS
J Gastroenterol Hepatol; 2011 Jun; 26(6):987-95. PubMed ID: 21198828
[TBL] [Abstract][Full Text] [Related]
22. A novel liver stiffness measurement-based prediction model for cirrhosis in hepatitis B patients.
Kim BK; Han KH; Park JY; Ahn SH; Chon CY; Kim JK; Paik YH; Lee KS; Park YN; Kim DY
Liver Int; 2010 Aug; 30(7):1073-81. PubMed ID: 20492510
[TBL] [Abstract][Full Text] [Related]
23. Will non-invasive markers replace liver biopsy for diagnosing and staging fibrosis in non-alcoholic steatohepatitis?
Hashimoto E; Farrell GC
J Gastroenterol Hepatol; 2009 Apr; 24(4):501-3. PubMed ID: 19368628
[No Abstract] [Full Text] [Related]
24. Contemporary assessment of hepatic fibrosis.
Bonder A; Tapper EB; Afdhal NH
Clin Liver Dis; 2015 Feb; 19(1):123-34. PubMed ID: 25454300
[TBL] [Abstract][Full Text] [Related]
25. Determination of reliability criteria for liver stiffness evaluation by transient elastography.
Boursier J; Zarski JP; de Ledinghen V; Rousselet MC; Sturm N; Lebail B; Fouchard-Hubert I; Gallois Y; Oberti F; Bertrais S; Calès P;
Hepatology; 2013 Mar; 57(3):1182-91. PubMed ID: 22899556
[TBL] [Abstract][Full Text] [Related]
26. [Noninvasive diagnosis of fatty liver disease].
Qu Y; Lu LG
Zhonghua Gan Zang Bing Za Zhi; 2010 Feb; 18(2):155-7. PubMed ID: 20196962
[No Abstract] [Full Text] [Related]
27. The validity of serum markers for fibrosis staging in chronic hepatitis B and C.
Li J; Gordon SC; Rupp LB; Zhang T; Boscarino JA; Vijayadeva V; Schmidt MA; Lu M;
J Viral Hepat; 2014 Dec; 21(12):930-7. PubMed ID: 24472062
[TBL] [Abstract][Full Text] [Related]
28. The APRI and the RVR.
Snyder N; Petersen JR
J Clin Gastroenterol; 2009; 43(5):500-1. PubMed ID: 19098684
[No Abstract] [Full Text] [Related]
29. Liver stiffness measurement by transient elastography in clinical practice.
Sporea I; Sirli R; Deleanu A; Popescu A; Cornianu M
J Gastrointestin Liver Dis; 2008 Dec; 17(4):395-9. PubMed ID: 19104699
[TBL] [Abstract][Full Text] [Related]
30. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan.
Sasso M; Miette V; Sandrin L; Beaugrand M
Clin Res Hepatol Gastroenterol; 2012 Feb; 36(1):13-20. PubMed ID: 21920839
[TBL] [Abstract][Full Text] [Related]
31. Characteristics and outcomes of chronic liver disease patients with acute deteriorated liver function by severity of underlying liver disease.
Hong YS; Sinn DH; Gwak GY; Cho J; Kang D; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
World J Gastroenterol; 2016 Apr; 22(14):3785-92. PubMed ID: 27076763
[TBL] [Abstract][Full Text] [Related]
32. [Factors associated with liver stiffness in chronic liver disease].
Lee DM; Moon EJ; Hwang JA; Lee MS; Cheong JY; Cho SW; Kim YB; Kim DJ; Hwang SG; Yang JM
Korean J Hepatol; 2009 Dec; 15(4):464-73. PubMed ID: 20037265
[TBL] [Abstract][Full Text] [Related]
33. Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study.
Afdhal NH; Bacon BR; Patel K; Lawitz EJ; Gordon SC; Nelson DR; Challies TL; Nasser I; Garg J; Wei LJ; McHutchison JG
Clin Gastroenterol Hepatol; 2015 Apr; 13(4):772-9.e1-3. PubMed ID: 25528010
[TBL] [Abstract][Full Text] [Related]
34. Vibration-controlled transient elastography: a practical approach to the noninvasive assessment of liver fibrosis.
Tapper EB; Afdhal NH
Curr Opin Gastroenterol; 2015 May; 31(3):192-8. PubMed ID: 25730177
[TBL] [Abstract][Full Text] [Related]
35. Non-invasive evaluation of hepatic fibrosis for type C chronic hepatitis.
Tatsumi C; Kudo M; Ueshima K; Kitai S; Ishikawa E; Yada N; Hagiwara S; Inoue T; Minami Y; Chung H; Maekawa K; Fujimoto K; Kato M; Tonomura A; Mitake T; Shiina T
Intervirology; 2010; 53(1):76-81. PubMed ID: 20068346
[TBL] [Abstract][Full Text] [Related]
36. Noninvasive markers of liver fibrosis in Latin America and Mexico.
Uribe M; Gutiérrez-Grobe Y; Kobashi-Margáin RA; Méndez-Sánchez N
Ann Hepatol; 2010; 9 Suppl():43-8. PubMed ID: 20713995
[No Abstract] [Full Text] [Related]
37. Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease.
Alkhouri N; Sedki E; Alisi A; Lopez R; Pinzani M; Feldstein AE; Nobili V
Liver Int; 2013 Jan; 33(1):79-85. PubMed ID: 23146095
[TBL] [Abstract][Full Text] [Related]
38. Fibroscan and FibroTest/FibroMax to assess liver fibrosis/cirrhosis in patients with chronic HBV and HCV infection in Georgia.
Dolmazashvili E; Zhamutashvili M; Svanidze M; Nizharadze N; Abutidze A
Georgian Med News; 2008 Dec; (165):83-7. PubMed ID: 19124923
[TBL] [Abstract][Full Text] [Related]
39. A practical scoring system for predicting cirrhosis in patients with chronic viral hepatitis.
Cheong JY; Um SH; Seo YS; Shin SS; Park RW; Kim DJ; Hwang SG; Lee YJ; Cho M; Yang JM; Kim YB; Park YN; Cho SW
Hepatogastroenterology; 2012; 59(120):2592-7. PubMed ID: 23178625
[TBL] [Abstract][Full Text] [Related]
40. Cryptogenic cirrhosis: a vanishing entity.
Desai HG
J Assoc Physicians India; 2009 Nov; 57():751-4, 759. PubMed ID: 20329442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
